论文部分内容阅读
目的 确定我国心功能不全患者对比索洛尔的耐受剂量范围和安全性。方法 入选因冠心病、扩张型心肌病或高血压而导致的心功能不全患者 74 6例 ,在基础治疗外加用比索洛尔。比索洛尔初始剂量为 1 2 5mg ,每日一次 ,逐渐加量至 2 5 0、3 75、5 0 0、7 5 0、10 0 0mg等。每位患者均达到并维持所能耐受的最大剂量至试验结束 ,随访时间为 1年。结果 可供统计学分析的病例为730例 ,其中 81 1%的患者服用比索洛尔≥ 5 0 0mg。在试验过程中 ,因药物不良反应而退出研究的有 15例 (2 1% )。 8例死亡 ,经研究者判定可能与研究药物无关。结论 我国心功能不全患者对比索洛尔的耐受剂量与国外相似 ,基础治疗加 β 受体阻滞剂长期治疗能改善心力衰竭患者的心功能 ,提高左室射血分数。
Objective To determine the tolerated dose range and safety of propofol in patients with cardiac dysfunction. Methods A total of 746 patients with heart failure due to coronary heart disease, dilated cardiomyopathy or hypertension were enrolled in this study. Bisoprolol was added to the basic treatment. Bisoprolol initial dose of 125mg, once daily, and gradually added to 250,375,5 0 0,7 5 0,10 0 0mg and so on. Each patient achieved and maintained the maximum tolerated dose to the end of the trial, followed up for 1 year. Results Of the 730 cases available for statistical analysis, 81 1% of patients took bisoprolol ≥ 500 mg. In the course of the trial, 15 patients (21%) dropped out of the study because of adverse drug reactions. 8 died, the researchers determined may not be related to the study drug. Conclusions The tolerability of propofol versus that of tobolol in our patients with cardiac insufficiency is similar to that of other countries. Long-term treatment with beta-blocker and basic therapy can improve cardiac function and increase left ventricular ejection fraction in patients with heart failure.